SeraCare Launches Expanded Offering of Biosynthetic Somatic Tumor Reference Materials for NGS-based Tumor Profiling Assays
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
Swift Biosciences, developer of innovative technologies for genomics research, and SeraCare Life Sciences, a manufacturer and leading partner to global in-vitro diagnostics manufacturers, has announced a partnership to accelerate development of a novel circulating tumor DNA reference material.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers and clinical diagnostics laboratories announces two important development milestones to their growing portfolio of next‐generation sequencing (NGS)‐based tools for Precision Medicine.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today that the company’s precision medicine business unit has launched its second product in a growing line of reference materials for next‐generation sequencing (NGS)‐based tumor profiling assays.
SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today, that it has launched its rebranding initiative as part of the company’s expanding capabilities for the support of advanced diagnostics development.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today at the American Association of Clinical Chemistry (AACC) meeting that it has signed a licensing agreement with the University of California, San Francisco (UCSF) for the use of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast cell line material as a component for creating “patient-like” reference materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal abnormalities.
Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.
SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced today an expansion and upgrade to their Gaithersburg, MD, R&D facility.
SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced the formation of a new business unit focused on the development of technologies and products to help enable the safe and effective expansion of precision medicine-driven diagnostics.
Select your country.
